{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-017289","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.618920+00:00","generated_at":"2026-06-15T01:12:00.374307+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Celcuity Q1 2023 net loss $11.9M; Phase 1b gedatolisib shows median PFS 48.6 months","bullets":["Net loss of $11.9M ($0.55 loss per share) vs $7.9M ($0.53 loss per share) in Q1 2022.","R&D expenses $11.3M, up from $6.7M, driven by VIKTORIA-1 Phase 3 trial costs.","Cash and short-term investments $157.5M at March 31, 2023.","Phase 1b gedatolisib data: median PFS 48.6 months in treatment-naïve HR+/HER2- advanced breast cancer.","VIKTORIA-1 Phase 3 enrollment on track for primary analysis of PIK3CA WT subgroup in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-017289","json":"https://secwatch.observer/filing/0001493152-23-017289.json","markdown":"https://secwatch.observer/filing/0001493152-23-017289.md","text":"https://secwatch.observer/filing/0001493152-23-017289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315223017289/0001493152-23-017289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315223017289/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:12:00.374307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e17d4cf076b324842ddd55949f8c3624fa3d8c78","claim":"Celcuity Inc. reported first quarter ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $11.9 million, EPS $0.55 loss per share.","evidence_excerpt":"Net loss for the first quarter of 2023 was $11.9 million, or $0.55 loss per share, compared to a net loss of $7.9 million, or $0.53 loss per share, for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000149315223017289/0001493152-23-017289-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the first quarter of 2023 was $11.9 million"},{"label":"EPS","value":"$0.55 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}